Man Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Man Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Hold	0	–	–	–	1603
2022 Q2	–	Sell	-23,855	Closed	-$382K	–	1756
2022 Q1	$388K	Buy	+23,855	New	+$374K	﹤0.01%	1674
2021 Q1	–	Sell	-61,718	Closed	-$1.52M	–	2040
2020 Q4	$1.52M	Sell	61,718 -57,979	-48%	-$1.92M	0.01%	1286
2020 Q3	$4.96M	Sell	119,697 -10,441	-8%	-$480K	0.02%	821
2020 Q2	$6.24M	Buy	+130,138	New	+$10.1M	0.03%	568
2020 Q1	–	Sell	-12,774	Closed	-$1.58M	–	1958
2019 Q4	$1.58M	Sell	12,774 -22,914	-64%	-$2.05M	0.01%	1388
2019 Q3	$2.37M	Buy	35,688 +28,496	+396%	+$1.91M	0.01%	1191
2019 Q2	$572K	Sell	7,192 -8,735	-55%	-$782K	﹤0.01%	1644
2019 Q1	$1.78M	Buy	15,927 +11,165	+234%	+$1.22M	0.01%	1386
2018 Q4	$480K	Buy	4,762 +424	+10%	+$43.9K	﹤0.01%	1640
2018 Q3	$548K	Sell	4,338 -686	-14%	-$72.6K	﹤0.01%	1817
2018 Q2	$422K	Sell	5,024 -276	-5%	-$20.2K	﹤0.01%	1847
2018 Q1	$326K	Buy	+5,300	New	+$319K	﹤0.01%	1808

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Man Group's ICPT Position: Q1 2023 in Review

Man Group held its Intercept Pharmaceuticals, Inc. (ICPT) position steady in Q1 2023 at 0 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #1603.

Man Group first reported a position in ICPT in Q1 2018 and has held it in 12 quarters since. The position peaked at $6.24M in Q2 2020. 144 funds tracked by Wall St. Rank hold ICPT as of Q1 2023.

Man Group held 0 shares of Intercept Pharmaceuticals, Inc. worth $383K as of Q1 2023.
Man Group left its Intercept Pharmaceuticals, Inc. share count unchanged in Q1 2023.
Intercept Pharmaceuticals, Inc. made up ﹤0.01% of Man Group's portfolio in Q1 2023, its #1603 holding.
Man Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2018 and has held it in 12 quarters since.
Man Group's Intercept Pharmaceuticals, Inc. position peaked at $6.24M in Q2 2020.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.